Singapore’s first clinical trials approved

Globally, 80% of the 800,000 new liver cancer cases are diagnosed in Asia Pacific, including China, Vietnam, Thailand, Indonesia, South Korea and Singapore. Liver cancer is the world’s third most deadly cancer with very limited treatment options and poor treatment outcome. There is currently no effective treatment available for liver cancer relapsed patients post-liver transplantation.

A Singapore based Biotech company has gained approval for its first clinical trial for a product named LioCyxTM  from Health Science Authority (HAS) Singapore, to conduct Phase 1/II multicenter clinical trial for the utilization of this treatment for relapsed liver cancer in post-liver transplantation patients. The treatment utilizes precision T cell receptor (TCR) immune cell therapy to combat the Hepatitis V virus (HBV)-related liver cancer.